PX91:FRA
Filana Therapeutics Inc
€1.11
arrow_downward
-1.25%(-0.014) 1D
Jun 12, 10:00:00 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PX91...
Open
€1.11
High
€1.11
Low
€1.11
Mkt. cap
60.38M
Avg. vol.
318.00
Volume
0.00
52-wk high
€3.90
52-wk low
€0.99
No. of employees
19
Open
€1.11
High
€1.11
Low
€1.11
Mkt. cap
60.38M
Avg. vol.
318.00
Volume
0.00
52-wk high
€3.90
52-wk low
€0.99
No. of employees
19
News stories
From sources across the web
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
About Filana Therapeutics Inc
CEO-
Employees19
Founded1998
HeadquartersAustin, Texas, United States
SectorPharmaceutical industry
Websitepaintrials.com
AI content may include mistakes. Learn more